Key Highlights
- Moleculin Biotech shares rose 6.12% to $0.60 at last closing after spiking intraday on new preclinical cancer data.
- New research presented at a major cancer conference suggests Annamycin's antitumor activity is partially driven by CD8+ T cell immune activity in pancreatic tumor models.
- The company stressed that Annamycin is not currently in clinical development for pancreatic cancer, and the results are preclinical rather than from human trials.
- Moleculin's lead program remains the MIRACLE trial testing Annamycin in acute myeloid leukemia, with unblinding anticipated between December 2026 and February 2027.
Moleculin Biotech (NASDAQ:MBRX) Penny Stock, a Houston-area clinical-stage cancer drug developer, spiked during Friday's session before closing higher on the Nasdaq Composite after announcing new preclinical data for its lead drug candidate, Annamycin, also known by the proposed name naxtarubicin. The data was presented at the American Association for Cancer Research Special Conference on Pancreatic Cancer in San Diego.
The presentation's title summarized the claim directly: turning cold pancreatic tumors hot, with Annamycin's antitumor activity partially mediated by CD8+ T cell cytotoxicity. In plain terms, researchers tested Annamycin in laboratory models of pancreatic cancer and found that part of its tumor-fighting activity came from CD8+ T cells, the immune cells that directly kill cancerous cells, with the rest coming from the drug's direct chemotherapy effect.
Latest Developments
Oncologists describe tumors as "cold" or "hot" based on how visible they are to the immune system. Hot tumors are infiltrated by immune cells and tend to respond better to immunotherapy drugs such as checkpoint inhibitors, while cold tumors have few immune cells inside them and tend to resist those drugs. Pancreatic cancer is one of the best-known cold-tumor examples and remains one of the deadliest cancers with limited treatment options, making any approach that could make it more visible to the immune system scientifically notable.
Moleculin's CEO Walter Klemp described the immune finding as an unexpected additional benefit that could open the door to combination approaches, and linked it to the company's separate immune-modulating program, WP1066, aimed at brain tumors and pancreatic cancer. The company was explicit that preclinical results may not predict results in humans, and that Annamycin is not in clinical development for pancreatic cancer.
Financial and Business Position
Moleculin's main focus is acute myeloid leukemia, an aggressive blood cancer. Annamycin is an anthracycline, redesigned according to the company to overcome multidrug resistance and avoid the cardiotoxicity common to that drug class. Its lead program is the MIRACLE trial, a pivotal Phase 2/3 study testing Annamycin combined with cytarabine in patients with relapsed or refractory leukemia.
Blinded interim data from the first 45 patients showed complete remission rates in both Annamycin arms well above the control arm, with enrollment expected to reach 90 patients in September 2026 and unblinding anticipated between December 2026 and February 2027. Moleculin reported about $7.3 million of cash at the end of June and, including about $9.3 million raised after the quarter, expects to fund operations into the first quarter of 2027.
Stock-Market Context
For a small biotech, a well-framed scientific result at a major cancer meeting can attract a burst of buying, especially when it hints at a new use for an existing drug candidate. The gap between laboratory data and an approved treatment remains very wide, and the stock gave back part of its intraday spike before closing.
The Gap Between Lab Data and a Real Program
Investors are watching for the full AACR presentation with detailed data on which models were used and how large the immune effect was, confirmation that MIRACLE trial enrollment reached 90 patients, and any decision to test Annamycin in pancreatic cancer in humans, which would turn this preclinical headline into an actual program. With a cash runway into early 2027, additional financing that could dilute existing holders also remains a near-term consideration.






Please wait processing your request...